Estudio de adecuación a la ficha técnica de las prescripciones de trastuzumab en un hospital de tercer nivel
2012
Introduction: This study compares trastuzumab’s actual conditions of use in clinical practice
with those officially described on its summary of product characteristics. We also measure the
cost associated with its use. Methods: Observational study of the prescription/indication of trastuzumab in a tertiary hospital
from January 2006 to 31 December 2007. We analysed whether trastuzumab use in clinical
practice complied with its summary of product characteristics, concerning the following: HER2
over expression, indication (breast cancer), treatment plan, line of treatment, dosage, frequency
and number of cycles. To measure cost, we calculated the total number of milligrams
used and then multiplied it by the laboratory’s sale price per milligram plus VAT.
Results: All patients (n = 77) used trastuzumab for breast cancer. Sixty-two point two percent
of patients presented with HER2+++ over expression. Twenty-nine treatment plans were used,
that were not authorised on the summary of product characteristics. The total trastuzumab
cost during the study period was D1537 622.73.
Conclusions: Although trastuzumab is always used for breast cancer, it is used in conditions
other than those described on its summary of product characteristics, both for HER2 over
expression and treatment plans.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
3
Citations
NaN
KQI